Delcath Systems, Inc. (NYSE:DCTH) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $20.00 for the company and are anticipating that the company will post ($1.38) EPS for the current quarter, according to Zacks. Zacks has also given Delcath Systems an industry rank of 145 out of 254 based on the ratings given to its competitors.

Separately, Roth Capital restated a “buy” rating on shares of Delcath Systems in a report on Thursday, June 4th.

DCTH traded down $0.19 on Friday, hitting $8.53. The company had a trading volume of 57,309 shares, compared to its average volume of 41,483. Delcath Systems has a 1-year low of $5.15 and a 1-year high of $95.90.

Delcath Systems (NYSE:DCTH) last posted its earnings results on Thursday, May 14th. The company reported ($108.07) earnings per share for the quarter. The company had revenue of $0.29 million during the quarter.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.

Featured Article: When can a hold rating present a buying opportunity?

Get a free copy of the Zacks research report on Delcath Systems (DCTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.